Gastrointestinal Bleeding is Blood Loss in the Digestive Tract, Classified as Upper or Lower. Ischemic Heart Disease is Due to Blocked Heart Arteries. Antiplatelet Drugs Help Prevent Heart Attacks But Increase GI Bleeding Risk, Especially When Used Together as Dual Therapy.

ConditionsGastro Intestinal Bleeding Ischaemic Heart Diseases Antiplatelet Drugs Antiplatelet Drug-related Gastrointestinal Injury

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorAssiut University

About this trial

Gastrointestinal bleeding is blood loss in the digestive tract, classified as upper or lower. Ischemic heart disease is due to blocked heart arteries. Antiplatelet drugs help prevent heart attacks but increase GI bleeding risk, especially when used together as dual therapy. This study aims to compare the prevalence and risk of gastrointestinal bleeding in ischemic heart disease patients on single versus dual antiplatelet therapy, and to explore strategies for reducing gastrointestinal bleeding in these patients, enhancing treatment safety without compromising cardiovascular protection.

Eligibility criteria

Qualifiers

Patients (aged 18 years old and older) who were diagnosed ischemic heart disease on single or dual antiplatelet therapy and developed gastrointestinal bleeding (manifestation of hematemesis, melena or bleeding per rectum).

Disqualifiers

Patients on anticoagulant.

Patients with bleeding tendencies.

Individuals with other comorbidities.

patients with acute coronary syndrome.

Trial design

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Locations

This trial has no locations

Sponsors and collaborators

Assiut University

Lead sponsor

Source ClinicalTrials.gov